According to a new press release, “Schrödinger, Inc. today announced it has entered into a three-year agreement with Google Cloud to substantially increase the speed and capacity of its physics-based computational platform for drug discovery. As part of the agreement, Schrödinger has selected Google Cloud as the preferred cloud platform for its leading simulation software. The strategic partnership gives Schrödinger’s drug discovery team access to the capacity equivalent of the world’s most powerful supercomputers by harnessing thousands of Google Cloud GPUs, which are designed to accelerate complex processes such as large-scale physics-based methods and machine learning through parallel computing. This expanded capacity is designed to further enable Schrödinger and its drug discovery collaborators to rapidly predict critical properties of billions of molecules per week.”

Shane Brauner, Schrödinger’s Chief Information Officer, commented, “We’re excited to harness Google Cloud’s highly scalable system to run extensive free energy calculations to assess binding affinities through our compute-intensive FEP+ application. This partnership also enables us to further leverage BigQuery to analyze important molecular properties nearly instantaneously… This partnership is expected to allow us to expand the use of our physics-based computational platform to continue to rapidly explore very large swaths of chemical space.”

Read more at Business Wire.

Image used under license from Shutterstock.com